138 related articles for article (PubMed ID: 23661306)
21. Recurrent
Pareja F; Da Cruz Paula A; Murray MP; Hoang T; Gularte-Mérida R; Brown D; da Silva EM; Sebastiao APM; Giri DD; Weigelt B; Reis-Filho JS; Brogi E
J Clin Pathol; 2019 Mar; 72(3):258-262. PubMed ID: 30467240
[TBL] [Abstract][Full Text] [Related]
22. MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression.
Tan WJ; Chan JY; Thike AA; Lim JC; Md Nasir ND; Tan JS; Koh VC; Lim WK; Tan J; Ng CC; Rajasegaran V; Nagarajan S; Bay BH; Teh BT; Tan PH
J Clin Pathol; 2016 Oct; 69(10):858-65. PubMed ID: 27056456
[TBL] [Abstract][Full Text] [Related]
23. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
24. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
[TBL] [Abstract][Full Text] [Related]
25. MED12 is frequently mutated in ovarian and other adnexal leiomyomas.
Li Z; Maeda D; Kudo-Asabe Y; Tamura D; Nanjo H; Hayashi A; Ikemura M; Fukayama M; Goto A
Hum Pathol; 2018 Nov; 81():89-95. PubMed ID: 29944972
[TBL] [Abstract][Full Text] [Related]
26. MED12 exon 2 mutations in phyllodes tumors of the breast.
Nagasawa S; Maeda I; Fukuda T; Wu W; Hayami R; Kojima Y; Tsugawa K; Ohta T
Cancer Med; 2015 Jul; 4(7):1117-21. PubMed ID: 25865354
[TBL] [Abstract][Full Text] [Related]
27. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K; Sasaki T; Tanabe M; Seto Y
Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
[TBL] [Abstract][Full Text] [Related]
28. Detection of MED12 mutations in mesenchymal components of uterine adenomyomas.
Kito M; Maeda D; Kudo-Asabe Y; Tamura D; Makino K; Sageshima M; Nanjo H; Terada Y; Goto A
Hum Pathol; 2021 Mar; 109():31-36. PubMed ID: 33259844
[TBL] [Abstract][Full Text] [Related]
29. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
30. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
31. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
32. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
33. Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.
Mäkinen N; Heinonen HR; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Br J Cancer; 2014 Apr; 110(9):2246-9. PubMed ID: 24642626
[TBL] [Abstract][Full Text] [Related]
34. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
[TBL] [Abstract][Full Text] [Related]
35. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
37. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
[TBL] [Abstract][Full Text] [Related]
38. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.
Mäkinen N; Heinonen HR; Moore S; Tomlinson IP; van der Spuy ZM; Aaltonen LA
Oncotarget; 2011 Dec; 2(12):966-9. PubMed ID: 22182697
[TBL] [Abstract][Full Text] [Related]
39. Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade.
Yoon N; Bae GE; Kang SY; Choi MS; Hwang HW; Kim SW; Lee JE; Nam SJ; Gong G; Lee HJ; Bae YK; Lee A; Cho EY
Genes Chromosomes Cancer; 2016 Jun; 55(6):495-504. PubMed ID: 26856273
[TBL] [Abstract][Full Text] [Related]
40. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
